Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Integral Health Asset Management LLC

Integral Health Asset Management LLC decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 25.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 300,000 shares of the biopharmaceutical company’s stock after selling 100,000 shares during the period. Integral Health Asset Management LLC’s holdings in Catalyst Pharmaceuticals were worth $6,261,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of Catalyst Pharmaceuticals by 9.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after acquiring an additional 33,888 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares during the period. Allspring Global Investments Holdings LLC boosted its position in Catalyst Pharmaceuticals by 13.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company’s stock valued at $8,710,000 after purchasing an additional 50,888 shares during the period. Redhawk Wealth Advisors Inc. acquired a new position in Catalyst Pharmaceuticals during the 4th quarter valued at approximately $1,273,000. Finally, Spire Wealth Management boosted its position in Catalyst Pharmaceuticals by 1,342.9% during the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 13,429 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock opened at $23.37 on Monday. The business’s fifty day moving average price is $22.99 and its two-hundred day moving average price is $22.40. The company has a market capitalization of $2.85 billion, a P/E ratio of 19.81, a PEG ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.75 and a 1-year high of $26.16.

Wall Street Analysts Forecast Growth

CPRX has been the subject of a number of analyst reports. Robert W. Baird boosted their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Stephens restated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Finally, Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and an average target price of $32.29.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04% decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is owned by company insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.